Gossamer (GOSS) Form 4: 125K PSU Grant Tied to Seralutinib NDA

Rhea-AI Filing Summary

Caryn Peterson, Executive Vice President, Regulatory Affairs of Gossamer Bio, Inc. (GOSS), reported the acquisition of 125,000 performance stock units on 10/01/2025. The award is a performance stock unit grant that vests in full upon the earlier of (i) approval of a new drug application for seralutinib or (ii) a change in control, in either case on or before the fourth anniversary of the grant date, and is subject to the reporting person’s continuous service. After the transaction the reporting person beneficially owns 174,833 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025.

Positive

• 125,000 performance stock units granted to EVP, Regulatory Affairs on 10/01/2025

Negative

• None.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Peterson Caryn

Role EVP, Regulatory Affairs

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	125,000	$0.00	--

Holdings After Transaction: Common Stock — 174,833 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Peterson Caryn

(Last) (First) (Middle)

3115 MERRYFIELD ROW, SUITE 120

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Gossamer Bio, Inc. [ GOSS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Regulatory Affairs

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		A		125,000(1)	A	$0	174,833	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents performance stock unit award, which will vest in full upon the earlier of (i) the approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, and subject to the Reporting Person's continuous service to the Issuer.

Remarks:

	/s/ Jeff Boerneke, Attorney-in-Fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the GOSS Form 4 filed for Caryn Peterson report?

The Form 4 reports a grant of 125,000 performance stock units to Caryn Peterson on 10/01/2025 and beneficial ownership of 174,833 shares following the transaction.

When do the 125,000 performance stock units vest?

They vest in full upon the earlier of (i) approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, subject to continuous service.

What is the reporting person’s role at Gossamer Bio (GOSS)?

The reporting person is listed as an Officer with the title EVP, Regulatory Affairs and is also a Director on the form.

What is the transaction date and filing date on the Form 4?

The transaction date is 10/01/2025 and the Form 4 bears a signature by an attorney-in-fact dated 10/02/2025.

Does the Form 4 specify a purchase price for the units?

The Form 4 shows $0 under price for the reported acquisition of the performance stock units.